PCM
EFTR

Penserra Capital Management’s eFFECTOR Therapeutics, Inc. Common Stock EFTR Stock Holding History

Penserra Capital Management’s Portfolio EFTR Stock Details EFTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-204
Closed -$7K – 1279
2022
Q2 		$7K Buy
204
+59
+41% +$3.57K ﹤0.01% 1327
2022
Q1 		$14K Buy
145
+25
+21% +$3.32K ﹤0.01% 1358
2021
Q4 		$24K Buy
+120
New +$27.9K ﹤0.01% 1217

Other funds holding EFTR

SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
ECM
Evolution Capital Management Crystal Bay, Nevada $29M AUM 2.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Penserra Capital Management's EFTR Position: Q3 2022 in Review

Penserra Capital Management sold out of eFFECTOR Therapeutics, Inc. Common Stock (EFTR) in Q3 2022, closing a stake of 204 shares — an estimated $7K sold.

Penserra Capital Management first reported a position in EFTR in Q4 2021 and held it in 3 quarters. The position peaked at $24K in Q4 2021. 27 funds tracked by Wall St. Rank hold EFTR as of Q3 2022.

  • Penserra Capital Management reported no remaining eFFECTOR Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 204 eFFECTOR Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $7K.
  • Penserra Capital Management first reported a position in eFFECTOR Therapeutics, Inc. Common Stock in Q4 2021 and held it in 3 quarters.
  • Penserra Capital Management's eFFECTOR Therapeutics, Inc. Common Stock position peaked at $24K in Q4 2021.
  • 27 funds tracked by Wall St. Rank held eFFECTOR Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.